SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Goldberg Marc E. (Last) (First) (Middle) C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET (Street) WATERTOWN MA 02472 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/20/2013	3. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ ENTA ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series E Convertible Preferred Stock	(1)	(1)	Common Stock	471,973	(1)	I	By BioVentures Investors Limited Partnership II(2)
Series G-2 Convertible Preferred Stock	(3)	(3)	Common Stock	132,494	(3)	I	By BioVentures Investors Limited Partnership II(2)
Stock Warrant (right to buy)	(4)	10/04/2017	Series 1 Non-Convertible Preferred Stock	123,260	0.01	I	By BioVentures Investors III Limited Partnership(5)
Stock Warrant (right to buy)	(4)	10/04/2017	Series 1 Non-Convertible Preferred Stock	25,221	0.01	I	By BioVentures Investors (Offshore) III Limited Partnership(6)

Explanation of Responses:

1. The Series E Convertible Preferred Stock has no expiration date, and each share of Series E Convertible Preferred Stock will convert automatically into approximately 0.30529 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.

2. These shares are held by BioVentures Investors Limited Partnership II, and are shares for which Mr. Goldberg may be deemed to share voting and investment control. Mr. Goldberg disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.

3. The Series G-2 Convertible Preferred Stock has no expiration date, and each share of Series G-2 Convertible Preferred Stock will convert automatically into approximately 0.23202 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.

4. This warrant is immediately exercisable.

5. Includes a warrant to purchase 123,260 shares of Series 1 Non-Convertible Preferred Stock held by BioVentures Investors III Limited Partnership. Mr. Goldberg may be deemed to be the indirect beneficial owner of the securities owned by BioVentures Investors III Limited Partrnership since he shares voting and investment control over the securities. Mr. Goldberg disclaims beneficial ownership of such warrant except to the extent of his pecuniary interest therein, if any.

6. Includes a warrant to purchase 25,221 shares of Series 1 Non-Convertible Preferred Stock held by BioVentures Investors (Offshore) III Limited Partnership. Mr. Goldberg may be deemed to be the indirect beneficial owner of the securities owned by BioVentures Investors (Offshore) III Limited Partrnership since he shares voting and investment control over the securities. Mr. Goldberg disclaims beneficial ownership of such warrant except to the extent of his pecuniary interest therein, if any.

Remarks:

	/s/ Marc E. Goldberg	03/20/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY



Know all by these presents,that

the undersigned hereby constitutes

and appoints each of Jay R. Luly,

Paul J. Mellett, and Nathaniel S.

Gardiner, or each of them acting

individually, the undersigned's

true and lawful attorney-in-fact

to:



(1) execute for and on behalf of

the undersigned a Form ID

application to be filed with the

Securities and Exchange Commission

to obtain EDGAR codes for the

undersigned;



(2) execute for and on behalf of

the undersigned Forms 3, 4, and 5

with respect to the securities

of Enanta Pharmaceuticals, Inc.

(the "Company") in accordance

with Section 16(a) of the

Securities and Exchange Act of

1934 and the rules thereunder;



(3) do and perform any and all

acts for and on behalf of the

undersigned which may be

necessary or desirable to

complete and execute any such

Form ID application or Form 3, 4,

or 5, complete and execute any

amendment or amendments thereto,

and timely file such forms with

the United States Securities and

Exchange Commission and any stock

exchange or similar authority; and



(4) take any other action of any

type whatsoever in connection with

the foregoing which, in the opinion

of such attorney-in-fact, may be

of benefit to, in the best interest

of, or legally required by, the

undersigned, it being understood

that the documents executed by such

attorney-in-fact on behalf of the

undersigned pursuant to this Power

of Attorney shall be in such form

and shall contain such terms and

conditions as such attorney-in-fact

may approve in such attorney-in-

fact's discretion.



The undersigned hereby grants to

each such attorney-in-fact full

power and authority to do and

perform any and every act and

thing whatsoever requisite,

necessary, or proper to be done in

the exercise of any of the rights

and powers herein granted, as fully

to all intents and purposes as the

undersigned might or could do if

personally present, with full

power of substitution or revocation,

hereby ratifying and confirming all

that such attorney-in-fact, or such

attorney-in-fact's substitute or

substitutes, shall lawfully do or

cause to be done by virtue of this

power of attorney and the rights

and powers herein granted.  The

undersigned acknowledges that the

foregoing attorneys-in-fact, in

serving in such capacity at the

request of the undersigned, are

not assuming, nor is the Company

assuming, any of the undersigned's

responsibilities to comply with

Section 16 of the Securities

Exchange Act of 1934, as amended.



This Power of Attorney shall

remain in full force and effect

until the undersigned is no longer

required to file Forms 3, 4, and 5

with respect to the undersigned's

holdings of and transactions in

securities issued by the Company,

unless earlier revoked by the

undersigned in a signed writing

delivered to the foregoing attorneys-

in-fact.



IN WITNESS WHEREOF, the undersigned

has caused this Power of Attorney to

be executed this 20th day of March

2013.



/s/ Marc E. Goldberg